NGD 95-1 oral neuropeptide Y antagonist data

NRGN announced interim results from a single, escalating dose Phase I safety trial in 75 overweight but otherwise healthy volunteers. The volunteers received placebo or one of six doses of NGD 95-1 in either a fed or fasted state. The company said the compound was safe and well-tolerated across a broad dose range. ...